Last reviewed · How we verify

NCT05216055: TAP

Transverse Abdominus Plane Block Study

Withdrawn Phase 2 Last updated 6 March 2023
What this trial tests

Phase 2 trial testing Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline in Colorectal Disorders. Withdrawn.

Timeline
19 April 2022
Primary endpoint
16 December 2022
27 December 2022

Quick facts

Lead sponsorUniversity of Colorado, Denver
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Start date19 April 2022
Primary completion16 December 2022
Estimated completion27 December 2022

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 100, any sex, with Colorectal Disorders or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study the effect of laparoscopic guided TAP block on opioid consumption and associated costs using a mixture of dexmedetomidine, dexamethasone, and ropivacaine versus Liposomal bupivacaine (Exparel®) in patients who undergo elective minimally invasive colorectal surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colorectal Disorders

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05216055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing